pSivida takes us on a fantastic voyage to the back of the eye

After developing several miniaturized, injectable drug delivery systems for the treatment of niche ocular diseases, pSivida (NASDAQ:PSDV; ASX:PVA) is now at the precipice of several blockbuster indications, including diabetic macular edema (DME), age-related macular degeneration (AMD) and glaucoma, with its next-generation Durasert device. And in early development is a new generation Tethadur platform that relies [...]

eSight eyes commercial launch this fall

Closely held eSight is set to begin the final stages of patient evaluation of its intelligent eyewear, setting the stage for a commercial launch in the fall. “We think this will make a big difference in the quality of people’s lives,” CEO Kevin Rankin says in an exclusive interview with BioTuesdays.com. “Our device will enable [...]

MacuCLEAR seeking financing for pivotal dry AMD trial

Closely held MacuCLEAR, with a successful proof-of-concept trial under its belt, is beating the bushes to raise $10 million to conduct the first of two safety and efficacy studies of its eye drop formulation to treat and prevent progression of the dry form of age-related macular degeneration (AMD), the leading cause of blindness in people [...]

ArcticDx develops next generation DNA test for AMD

ArcticDx has licensed exclusive world-wide commercial rights to a causative mutation in the HTRA1/ARMS2 gene from Regensberg University in Germany and screening for this important genetic variation has been incorporated into a next-generation version of Macula-Risk. Macula-Risk is the company’s DNA test that is intended as a prognostic test for patients who have been diagnosed [...]